Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor [...]
Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor [...]